JP2010522698A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010522698A5 JP2010522698A5 JP2010500036A JP2010500036A JP2010522698A5 JP 2010522698 A5 JP2010522698 A5 JP 2010522698A5 JP 2010500036 A JP2010500036 A JP 2010500036A JP 2010500036 A JP2010500036 A JP 2010500036A JP 2010522698 A5 JP2010522698 A5 JP 2010522698A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- methionine
- weight percent
- miu
- suspension
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 35
- 102100040018 Interferon alpha-2 Human genes 0.000 claims description 22
- 108010079944 Interferon-alpha2b Proteins 0.000 claims description 22
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 18
- 229960004452 methionine Drugs 0.000 claims description 15
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 claims description 13
- 229930195722 L-methionine Natural products 0.000 claims description 13
- 239000000725 suspension Substances 0.000 claims description 11
- 230000000694 effects Effects 0.000 claims description 9
- 239000007764 o/w emulsion Substances 0.000 claims description 9
- 206010008263 Cervical dysplasia Diseases 0.000 claims description 5
- 239000000232 Lipid Bilayer Substances 0.000 claims description 5
- 239000006071 cream Substances 0.000 claims description 4
- 230000002051 biphasic effect Effects 0.000 claims description 3
- 150000002632 lipids Chemical class 0.000 claims description 3
- 238000000034 method Methods 0.000 description 6
- 229930182817 methionine Natural products 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US90932407P | 2007-03-30 | 2007-03-30 | |
| US60/909,324 | 2007-03-30 | ||
| PCT/CA2008/000563 WO2008119160A1 (en) | 2007-03-30 | 2008-03-27 | Biphasic lipid-vesicle composition and method for treating cervical dysplasia by intravaginal delivery |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010522698A JP2010522698A (ja) | 2010-07-08 |
| JP2010522698A5 true JP2010522698A5 (cg-RX-API-DMAC7.html) | 2011-05-19 |
| JP5587762B2 JP5587762B2 (ja) | 2014-09-10 |
Family
ID=39807744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010500036A Expired - Fee Related JP5587762B2 (ja) | 2007-03-30 | 2008-03-27 | 膣内送達により子宮頸部異形成を治療するための二相性脂質小胞組成物および方法 |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US8945529B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2134353B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5587762B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20090130081A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2008234364B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2681565C (cg-RX-API-DMAC7.html) |
| CY (1) | CY1118794T1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK2134353T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2617063T3 (cg-RX-API-DMAC7.html) |
| HR (1) | HRP20170250T1 (cg-RX-API-DMAC7.html) |
| HU (1) | HUE033256T2 (cg-RX-API-DMAC7.html) |
| LT (1) | LT2134353T (cg-RX-API-DMAC7.html) |
| MX (1) | MX2009010405A (cg-RX-API-DMAC7.html) |
| PL (1) | PL2134353T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT2134353T (cg-RX-API-DMAC7.html) |
| SI (1) | SI2134353T1 (cg-RX-API-DMAC7.html) |
| TW (1) | TWI440477B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2008119160A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3008900B1 (fr) * | 2013-07-25 | 2018-03-30 | Centre Nat Rech Scient | Nanoparticules lipidiques multicompartimentees |
| US8986732B2 (en) * | 2013-08-12 | 2015-03-24 | Helix Biopharma Corporation | Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intravaginal delivery |
| US10159646B2 (en) * | 2013-08-12 | 2018-12-25 | Altum-Avro Pharma Partnership | Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intravaginal delivery |
| EP3041938A1 (en) | 2013-09-03 | 2016-07-13 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| US20150147382A1 (en) * | 2013-09-23 | 2015-05-28 | Exir Nano Sina Company | Topical liposomal compositions for delivering hydrophobic drugs and methods preparing same |
| EP3625345B1 (en) | 2017-05-18 | 2023-05-24 | ModernaTX, Inc. | Modified messenger rna comprising functional rna elements |
| CN111093633A (zh) * | 2017-05-26 | 2020-05-01 | 奥特姆医药公司 | 双相大麻素递送 |
| US11859215B2 (en) | 2017-11-22 | 2024-01-02 | Modernatx, Inc. | Polynucleotides encoding ornithine transcarbamylase for the treatment of urea cycle disorders |
| EP3714047A2 (en) | 2017-11-22 | 2020-09-30 | ModernaTX, Inc. | Polynucleotides encoding phenylalanine hydroxylase for the treatment of phenylketonuria |
| MX2021003015A (es) | 2018-09-13 | 2021-07-15 | Modernatx Inc | Polinucleotidos que codifican glucosa-6-fosfatasa para el tratamiento de la glucogenosis. |
| MA53615A (fr) | 2018-09-14 | 2021-07-21 | Modernatx Inc | Polynucléotides codant pour le polypeptide a1, de la famille de l'uridine diphosphate glycosyltransférase 1, pour le traitement du syndrome de crigler-najjar |
| MX2022003446A (es) * | 2019-09-23 | 2022-07-13 | Dds Res Inc | Composiciones de vesiculas lipidicas con agentes potenciadores de la penetracion. |
| WO2022204371A1 (en) | 2021-03-24 | 2022-09-29 | Modernatx, Inc. | Lipid nanoparticles containing polynucleotides encoding glucose-6-phosphatase and uses thereof |
| US20240216288A1 (en) | 2021-03-24 | 2024-07-04 | Modernatx, Inc. | Lipid nanoparticles containing polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits and uses thereof |
| US20240207444A1 (en) | 2021-03-24 | 2024-06-27 | Modernatx, Inc. | Lipid nanoparticles containing polynucleotides encoding phenylalanine hydroxylase and uses thereof |
| MX2023011157A (es) | 2021-03-24 | 2024-01-25 | Glo Pharma Inc | Peptidos y metodos para reducir la pigmentacion de la piel. |
| US20240376445A1 (en) | 2021-06-22 | 2024-11-14 | Modernatx, Inc. | Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide a1 for the treatment of crigler-najjar syndrome |
| JP2024543039A (ja) * | 2021-11-04 | 2024-11-19 | ジーエルオー ファーマ，インク． | 化粧品適用のための方法および組成物 |
| EP4562163A1 (en) | 2022-07-26 | 2025-06-04 | ModernaTX, Inc. | Engineered polynucleotides for temporal control of expression |
| WO2024130158A1 (en) | 2022-12-16 | 2024-06-20 | Modernatx, Inc. | Lipid nanoparticles and polynucleotides encoding extended serum half-life interleukin-22 for the treatment of metabolic disease |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5358708A (en) * | 1993-01-29 | 1994-10-25 | Schering Corporation | Stabilization of protein formulations |
| ATE195866T1 (de) | 1993-07-28 | 2000-09-15 | Pharmaderm Lab Ltd | Zweiphasige multilamellare lipidvesikel |
| IN184589B (cg-RX-API-DMAC7.html) * | 1996-10-16 | 2000-09-09 | Alza Corp | |
| US5993852A (en) | 1997-08-29 | 1999-11-30 | Pharmaderm Laboratories Ltd. | Biphasic lipid vesicle composition for transdermal administration of an immunogen |
| US6656499B1 (en) * | 1999-11-12 | 2003-12-02 | Pharmaderm Laboratories, Ltd. | Composition for transdermal and dermal administration of interferon-α |
| TWI272948B (en) | 2003-05-01 | 2007-02-11 | Ares Trading Sa | HSA-free stabilized interferon liquid formulations |
| EP1576952A1 (en) | 2004-03-18 | 2005-09-21 | OctoPlus Technologies B.V. | Hydrogel microspheres with improved release profile |
-
2008
- 2008-03-27 LT LTEP08733666.5T patent/LT2134353T/lt unknown
- 2008-03-27 EP EP08733666.5A patent/EP2134353B1/en active Active
- 2008-03-27 KR KR1020097022186A patent/KR20090130081A/ko not_active Ceased
- 2008-03-27 JP JP2010500036A patent/JP5587762B2/ja not_active Expired - Fee Related
- 2008-03-27 DK DK08733666.5T patent/DK2134353T3/en active
- 2008-03-27 PL PL08733666T patent/PL2134353T3/pl unknown
- 2008-03-27 AU AU2008234364A patent/AU2008234364B2/en not_active Ceased
- 2008-03-27 CA CA2681565A patent/CA2681565C/en active Active
- 2008-03-27 MX MX2009010405A patent/MX2009010405A/es active IP Right Grant
- 2008-03-27 HU HUE08733666A patent/HUE033256T2/hu unknown
- 2008-03-27 SI SI200831765A patent/SI2134353T1/sl unknown
- 2008-03-27 ES ES08733666.5T patent/ES2617063T3/es active Active
- 2008-03-27 WO PCT/CA2008/000563 patent/WO2008119160A1/en not_active Ceased
- 2008-03-27 HR HRP20170250TT patent/HRP20170250T1/hr unknown
- 2008-03-27 US US12/532,752 patent/US8945529B2/en active Active
- 2008-03-27 PT PT87336665T patent/PT2134353T/pt unknown
- 2008-03-28 TW TW097111592A patent/TWI440477B/zh not_active IP Right Cessation
-
2013
- 2013-03-22 US US13/849,451 patent/US20130216610A1/en not_active Abandoned
- 2013-03-22 US US13/849,455 patent/US20130224283A1/en not_active Abandoned
-
2017
- 2017-02-14 CY CY20171100200T patent/CY1118794T1/el unknown